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Abstract  
Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force. 
Introduction 
Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration 
leading to immobility, respiratory failure and premature death. As chronic inflammation and 
stress are implicated in DMD pathology, the efficacy of an anti-inflammatory and anti-stress 
intervention strategy in ameliorating diaphragm dysfunction was investigated.  
Methods 
Diaphragm muscle contractile function was compared in wild-type and dystrophin-deficient 
mdx mice treated with saline, anti-IL-6R antibodies (xIL-6R), the corticotrophin-releasing 
factor receptor 2 (CRFR2) agonist, urocortin 2 or both xIL-6R and urocortin 2.  
Results 
Combined treatment with xIL-6R and urocortin 2 rescued impaired force in mdx diaphragms. 
Mechanical work production and muscle shortening was also improved by combined drug 
treatment.  
Discussion 
Treatment which neutralizes peripheral IL-6 signaling and stimulates CRFR2 recovers force-
generating capacity and the ability to perform mechanical work in mdx diaphragm muscle. 
These findings may be important in the search for therapeutic targets in DMD. 
 
Keywords: Interleukin-6, corticotrophin-releasing factor, urocortin 2, mdx, diaphragm, 
monoclonal. 
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Introduction 
Patients with Duchenne muscular dystrophy (DMD) are deficient in the functional protein 
dystrophin, which protects muscle fibers from mechanical stresses induced by cellular 
contraction
1,2
. The most obvious and debilitating characteristic feature of DMD is the 
progressive degeneration and weakening of striated muscles resulting in severe disability and 
premature death
3
. Cardiopulmonary failure dominates disease morbidity in the later stages 
and pulmonary insufficiency is the leading cause of premature death
4
. As repeated 
contraction and load bearing on striated muscle determines the severity of the pathological 
signature in DMD muscle, continuous diaphragmatic contractions result in severe 
degeneration of this organ. Patients suffer reduced vital capacity, aberrant blood gas 
regulation and are prone to sleep-disordered breathing
5
. Indeed, artificial ventilation has 
proved effective in extending lifespan in DMD patients
6,7
.  
 
Dystrophin-deficient skeletal muscles exhibit altered calcium handling and abnormal 
regulation of reactive oxygen species and nitric oxide
8
. Additionally, chronic inflammation as 
evidenced by elevated levels of cytokines, leukocyte adhesion and complement system 
activation
9
, is likely to contribute to muscle dysfunction. Pro-inflammatory cytokines such as 
tumor necrosis factor (TNF)
10
 and interleukins (IL)-1 and -6
9
 are early indicators of the 
disease, and the inflammatory response worsens with disease progression. The pro-
inflammatory cytokine IL-6, is secreted by skeletal muscle following exercise and due to 
local inflammation
11,12
 but is also released by immune cells, neurons
13
 and epithelial cells
14
. 
Circulating IL-6 levels are elevated in DMD patients
15,16
 and in the diaphragm of dystrophin-
deficient mdx mice
17
. Although mdx mice generally exhibit a milder phenotype than the 
human disease, pathological changes in the diaphragm are faithfully recapitulated
18-20
, 
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making the mdx mouse appropriate for studying interventions seeking to ameliorate 
diaphragm dysfunction. The diaphragm muscle undergoes inflammation and becomes 
fibrotic, with collagen replacing functional fibers
22
, resulting in a substantial loss of force 
production
1,18,21
. Interestingly, Kostek et al. demonstrated that blocking IL-6 signaling with 
an IL-6 receptor antibody, raised levels of inflammatory markers in gastrocnemius muscle in 
mdx mice, with an 11% increase in hind limb strength, which failed to reach statistical 
significance. There was no effect on forelimb strength
23
. Conversely, in mdx diaphragm, this 
treatment strategy favored an anti-inflammatory response and improved muscle repair
24
. 
However, the functional effects of this strategy have not been assessed. 
 
DMD patients frequently exhibit co-morbid anxiety and depression
25
 and depression- and 
anxiety-like behaviors are also evident in mdx mice
26
. Indeed, amitriptyline, an anti-
depressant with anti-inflammatory effects caused alterations in circulating IL-6 levels 
associated with decreased inflammation in skeletal limb muscles
26
. Although mdx mice are 
stress-sensitive
26
, the hypothalamic-pituitary-adrenal (HPA) stress axis, which is activated by 
the binding of corticotrophin-releasing factor (CRF) to either CRF1 or CRF2 receptors 
(CRFR1 or CRFR2), appears to be intact
27
. Nonetheless, treatment with the CRFR2 agonist, 
urocortin2 (Uro2), reduced inflammation in skeletal muscle with an associated improvement 
in diaphragm function in mdx mice
28
, an effect attributed to increased muscle mass, 
modulated proteolysis and activation of anabolic signaling pathways
29
. Given that the current 
treatment for DMD, corticosteroids, are associated with unwanted side-effects, we sought to 
investigate whether more targeted treatment strategies using monoclonal IL-6 receptor (xIL-
6R) antibodies and/or Uro2, which have both been shown to be beneficial with regard to 
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dystrophinopathies, may be beneficial in terms of ameliorating diaphragm muscle 
dysfunction in the mdx mouse. 
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Material and Methods  
Ethical approval 
All experiments involving animals were conducted under national license in full accordance 
with European Union directives and following institutional animal ethics committee 
approval.  
 
Animals and Experimental Design 
Breeding pairs of dystrophin-deficient C57BL/10ScSn-Dmd
Mdx
/J (mdx, dystrophic) and 
C57BL/10ScSn wild type (WT) mice were purchased from Jackson Laboratories (Bar 
Harbor, Maine, U.S.A). Colonies were established and maintained in our institutional animal 
facility. Weaned mice were housed in groups of up to 4 per cage, and kept in a 12h light/12h 
dark
 
cycle (06:00-18:00 light hours), with
 
free access to drinking water and standard chow. 
Male mice were used for studies. Power calculations with an effect size of 2, power of 0.9 
and false positive rate (α) of 0.05, were used to determine group sizes of at least n=6 per 
group. Diaphragm tissue was harvested from animals used in a previously published study
30
. 
 
Diaphragm contractile function was assessed in untreated dystrophin-deficient mdx mice 
compared with WT mice (10 weeks old) confirming a significant respiratory muscle 
phenotype in mdx at this age (figure 1A). In the intervention study, a treatment regimen 
amended from previous studies
23,28
 was used. Mdx mice were randomly assigned to one of 
four groups, administered either saline (0.9% NaCl, 6 subcutaneous injections on alternate 
days over two weeks); anti-IL-6 receptor antibodies (xIL-6R, 0.2mg/kg body weight, 6 
subcutaneous injections on alternate days over two weeks (MR16-1, Chugai Pharmaceutical 
Co., Ltd, Tokyo, Japan); the CRFR2 agonist, urocortin 2 (Uro2, 30µg/kg body weight, 6 
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subcutaneous injections on alternate days over two weeks, Sigma Aldrich, St Louis, MO, 
USA) or a combination of both xIL-6R and Uro2 (6 subcutaneous injections on alternate days 
over two weeks). The experimental protocol is illustrated in Figure 1B. Animals were 
handled prior to the intervention to habituate animals to the associated stress and all 
injections were carried out by the same researcher. The investigator was not blinded to the 
intervention groups during data collection but subsequent analysis of the data was blinded. 
 
Tissue collection 
Mice were euthanized by decapitation and exsanguination. The diaphragm was excised and 
maintained in ice-cold 95% O2 / 5% CO2-bubbled Krebs solution consisting of (in mmol/L): 
NaCl, 117; KCl, 4.8; CaCl2, 2.5; MgCl2, 1.2; NaHCO3, 25; NaH2PO4, 1.2; and D-glucose 11.  
 
Ex vivo diaphragm muscle function 
A 3mm longitudinal strip of costal diaphragm was dissected with central tendon attached, 
extending to a rib. Cotton thread was tied to the central tendon and the preparation was 
arranged vertically in a tissue bath with 95% O2 / 5% CO2-bubbled Krebs solution maintained 
at 37
 º
C, with the rib tied to a hook at the base of the tissue holder and the tendon attached to 
a dual-mode force transducer (Aurora Scientific Inc., ON, Canada), which can isolate force 
and length independently allowing assessment of isometric and isotonic muscle performance. 
Electrical field stimulation of the diaphragm strips was evoked using two silver electrodes 
running vertically on either side of the diaphragm strip. The optimum length (LO) of each 
muscle preparation (i.e. the length which produces the maximal isometric twitch force in 
response to supra-maximal stimulation) was determined by incrementally adjusting a 
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micropositioner which altered muscle length between intermittent stimulations (1ms, 80V). 
Once determined, the muscle was held at LO for the duration of the experiment.  
 
A single twitch was elicited (supra-maximal voltage) and the twitch force, contraction time 
(time to peak force) and half-relaxation time (time for peak force to decay by 50%) were 
determined. Tetanic force in response to supra-maximal stimulation (100Hz, 300ms) was 
determined. Muscle peak shortening and maximum shortening velocity were determined 
under zero load conditions, the latter from the first detectable length change during the first 
30ms of each contraction
31–33
 .Mechanical work was calculated as the product of force x 
shortening (normalized to LO).  Mechanical power was calculated as the product of force x 
velocity (LO/s) of muscle shortening. Peak work and peak power were determined from 
contractions performed under varying load conditions
31–33
. 
 
Statistical Analysis 
The data are represented as mean values ± the standard error of the mean (SEM). Student t-
tests or one-way ANOVA (with Newman-Keuls post hoc tests) were used to compare 
parameters between groups; p<0.05 was considered statistically significant.   
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Results 
Combination treatment with xIL-6R and Uro2 recovers mdx diaphragm force 
production 
Mdx diaphragms have significantly reduced peak specific twitch force in response to a single 
supra-maximal stimulus compared with WT mice (Figure 2A). However, time to peak in mdx 
(30±2 ms) and WT (20±3 ms, p>0.05) and the time taken for the peak force to decay by 50% 
in mdx (20±5 ms) and WT (20±2 ms, p>0.05) mice were not different. In a separate cohort of 
mdx mice, assessment of diaphragm peak specific twitch force production determined that 
intervention with xIL-6R did not improve muscle function compared with saline-treated mdx 
mice (p>0.05). Diaphragms from mdx animals treated with Uro2 or the combined treatment 
of xIL-6R and Uro2 showed trends towards higher peak specific twitch force compared with 
saline-treated mdx mice (Figure 2A). In comparison to WT forces, combined treatment with 
xIL-6R and Uro2 in mdx mice, reflects a recovery to 97% of the control values. 
 
In response to tetanic stimulation (100Hz, 300ms), peak specific tetanic forces evoked in mdx 
diaphragms were significantly reduced compared with WT mice (Figure 2B). The weak peak 
specific tetanic force in saline-treated mdx diaphragm muscles was not significantly improved 
by treatment with either xIL-6R (p>0.05) or Uro2 alone (p>0.05). However, peak specific 
tetanic force was significantly increased following combined treatment with xIL-6R and 
Uro2 (Figure 2B) compared with saline-treated mdx, restoring values to 93% of the WT 
diaphragm.  
 
Work and power production in mdx diaphragm are improved by treatments 
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Further analysis of diaphragm muscle function in the mdx cohort demonstrated that peak 
specific shortening (L/Lo) was increased in xIL-6R-treated mdx diaphragms and combined 
xIL-6R- and Uro2-treated mdx diaphragms, but not Uro2-treated diaphragms compared with 
saline-treated mdx controls (Figure 3A). Peak diaphragm specific work, the product of 
contractile force and length of shortening, was significantly higher in mdx diaphragms from 
animals receiving the combined treatment of xIL-6R and Uro2 compared with saline-treated 
mdx, but not for either treatment alone (Figure 3B). Contraction kinetics were significantly 
improved in xIL-6R-treated group, but not different between saline treated and Uro2 or 
combination-treated mdx mice (Figure 3C). Peak specific power production of mdx 
diaphragm muscle strips was increased by all treatments compared with saline-treated mdx 
diaphragms (p<0.05 ANOVA), but this failed to achieve statistical significance for any of the 
three independent treatment groups (Figure 3D).   
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Discussion 
Diaphragm degeneration, fibrosis and dysfunction are evident in the mdx mouse, faithfully 
recapitulating human DMD
18,35,36
. Consistent with reports of reduced muscle strength, 
elasticity, twitch speed and fiber length
18
, we have similarly demonstrated that contraction 
force is attenuated in mdx diaphragm muscle. Our data demonstrate that an intervention 
treatment which inhibits peripheral IL-6 signaling and activates CRFR2 signaling has 
beneficial outcomes for diaphragm function in mdx mice, improving force-generating 
capacity and work production. 
 
Dystrophin anchors the extracellular matrix to cytoskeletal F-actin and is associated with 
intermediate muscle fiber filaments in the extracellular matrix protein complex. This complex 
spans the sarcolemma and provides skeletal muscle with protection from contraction-induced 
damage
1
; thus dystrophin deficiency is likely to alter the threshold for work-induced injury in 
muscle fibers. Isotonic muscle contractions that induce changes in muscle length can cause 
micro lesions in muscle fibers, which initiate a cascade of events that are detrimental to fiber 
health and function
37,38
. Thus, the isotonic properties of mdx muscle fibers are particularly 
relevant to understanding dystrophin-deficient muscle fiber pathology. Similar to other 
reports
18,19,39–41
, our study in 10-week old mdx mice established that diaphragm weakness is a 
hallmark signature of dystrophin loss. In response to single and tetanic stimuli mdx 
diaphragm muscle strips generated considerably lower contractile forces. As force generation 
is relative to the number of functional cross bridge connections made during skeletal muscle 
contraction
42,43
, muscle weakness is likely to be due to the loss of functional muscle fibers 
and an increase in connective tissue
22,44
. Changes in isometric contractile kinetics can 
indicate changes in muscle fiber type or changes in calcium handling in myocytes. However, 
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despite evidence that aged mdx mice exhibit slowing of actomyosin interactions
45
,
46
, we 
found no significant differences between WT and mdx mice in contractile kinetics, although 
the data should be viewed cautiously as the study may have been underpowered for this 
analysis. Peak specific tetanic force was the primary outcome measure in our study. Impaired 
mechanical work production has been reported previously in mdx diaphragm
47
. 
 
In addition to loss of the regenerative capacity of muscle fibers
48,49
 and weaker branched 
muscle
50
, loss of dystrophin from striated muscles is associated with inflammatory 
upregulation
9,51,52
. Indeed, the extent of the chronic inflammatory response is thought to 
predict the severity of the pathological changes associated with dystrophin-deficiency
9
. The 
potent anti-inflammatory effects of glucocorticoids, which are secreted following activation 
of the HPA axis by CRF, are the most effective therapy to date to slow down progression of 
DMD but are associated with unwanted side-effects. More specific targeting of immune 
and/or stress factors may provide novel therapeutic strategies with fewer side-effects. Indeed, 
inhibitors of NFκB have shown promise in improving mdx muscle pathology
53
 such as a 
recent study which revealed improvements in mdx diaphragm force following NFκB 
inhibition with ursodeoxycholic acid
54
. The pro-inflammatory cytokine IL-6, involved in 
skeletal muscle metabolism and maintenance and remodeling of myocytes, as well as 
regeneration after exercise and damage
55,56
, is reported to be elevated in mdx tissue
23,26,57
.  
 
The efficacy of blocking IL-6 signaling with xIL-6R in other inflammatory diseases such as 
rheumatoid arthritis and Castleman disease has been demonstrated
56,59
. Blocking IL-6 
signaling can result in muscle regeneration via immune modulation
60
 and mdx mice perform 
better on a treadmill test following 2 weeks of treatment with xIL-6R with associated 
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downregulation of diaphragm pro-inflammatory markers
61
. We have previously determined 
that xIL-6R administration prevents gastrointestinal dysfunction in the same animals as those 
used in the present study
30
. However, another report unexpectedly detected increased 
inflammation in limb muscles and found no changes in diaphragm muscle regeneration
23
. In 
our study, in vivo administration of xIL-6R alone over two weeks had only modest protective 
effects on mdx diaphragm function; mdx muscle force was not significantly changed by xIL-
6R treatment. The degree of muscle shortening and the velocity of this contraction was 
increased compared with saline-treated mdx tissue, but mdx diaphragm muscle peak work and 
peak power were only partially recovered and did not reach significance. As implicated by 
some studies using this treatment strategy, global reduction in inflammation is a possible 
mechanism underlying improved muscle function in mdx mice. However, Kostek and 
colleagues reported increased inflammation in mdx limb muscles following administration of 
xIL-6R after 5 weeks of treatment
23
. Evidence accruing is starting to suggest that the timing 
of the xIL-6R treatment may be crucial in terms of improved muscle function and altered 
inflammatory profiles
24
.  
 
We also investigated the potential therapeutic benefits of the CRFR2 agonist, Uro2. Previous 
studies demonstrated that activation of CRFR2 reduces skeletal muscle atrophy in limb 
muscles and increases muscle mass
29,62,63
. Uro2 has also recently been shown to improve 
skeletal muscle structure and function in mdx mice when administered in early life
28
. In our 
studies, 2 weeks of treatment with Uro2 in mdx mice increased diaphragm muscle force, 
although the effects failed to achieve statistical significance. Uro2 did not alter the contractile 
kinetics of mdx diaphragm contractions. These results differ to the observation of increased 
contractile kinetics following urocortin treatment reported by others
28
. However, as the Uro2 
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treatment group in our studies only had an n of 5, we acknowledge that this group was likely 
underpowered and this is a limitation of our study. CRFR2 agonists stimulate anabolic 
signaling pathways, promoting hypertrophy and reducing muscle necrosis, and have been 
shown to have beneficial effects in the limb muscles of mdx mice
29,40
. Uro2 probably 
promotes muscle hypertrophy and delays apoptosis of macrophages, as well as slowing 
muscle atrophy. However, it is worth noting that activation of CRFR2 may promote a pro-
inflammatory environment through NFĸB dependent induction of pro-inflammatory IL-8
64
, 
which could limit its potential use in the treatment of DMD.  
 
Since evidence exists for crosstalk between the stress factor, CRF and the immune mediator, 
IL-6 in neural
65
, smooth
66
 and cardiac tissues
67
, we assessed the potential benefits of a 
combination therapy of both xIL-6R and Uro2 to improve the inflammatory environment of 
mdx diaphragm muscle using different but complementary mechanisms. Our study revealed 
that combined drug therapy was most effective in restoring diaphragm force-generating 
capacity. Indeed, peak specific force and peak specific mechanical work production were 
equivalent in mdx mice receiving the combination treatment compared with WT diaphragm. 
Peak shortening, which occurs under zero load conditions was improved by xIL-6R 
treatment, which may relate to decreased muscle fibrosis and improved muscle mechanics. 
There was no significant effect of Uro-2 alone on peak shortening. As such the combination 
therapy was equivalent to xIL-6R alone. Improvement in peak shortening does not translate 
to improved peak work, as peak work occurs at 30-40% load (% of max force) in mouse 
diaphragm
30
. xIL-6R alone did not affect peak work, whereas the combination therapy 
significantly increased peak work, illustrating that the beneficial effect of the combined 
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therapy on mechanical work related predominantly to the positive inotropic effect of the drug 
interventions on muscle force.  
 
In conclusion, our findings show that xIL-6R and Uro2 treatments alone have modest 
beneficial effects on mdx diaphragm muscle function, but when administered together the 
inotropic effects are such that diaphragm peak force-generating capacity is impressively 
restored to WT values. Diaphragm muscle force is regarded as a clinically relevant parameter 
given that diaphragm weakness has prognostic value for patient outcome in the critical care 
setting
68
. Our study implicates IL-6R- and CRFR-mediated signaling in dystrophin-deficient 
respiratory muscle pathophysiology and has identified a combinational therapy which 
restores aspects of diaphragm function in the dystrophic mdx mouse, representing a strategy 
worthy of further consideration in the search for therapies for the treatment of DMD. 
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Abbreviations: Ca
2+
, calcium; CRF, corticotropin releasing factor; CRFR, CRF receptor; 
HPA, hypothalamic-pituitary-adrenal; IL, interleukin; IL-6R, interleukin-6 receptor; xIL-6R, 
anti-IL-6R. 
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Figure Legends  
Figure 1: Experimental protocol 
A: The flow chart shows the experimental protocol to establish the baseline characteristics of 
muscle function in wildtype (WT) and mdx diaphragms. B: The flow chart illustrates the 
experimental protocol in the interventions study which compares mdx mice treated with 
saline, anti-interleukin-6 receptor antibodies (xIL-6R), urocortin 2 (Uro2) or a combination 
treatment with both xIL-6R and Uro2. Behavioral assessments on day 13 have been 
previously published (Manning et al, 2016). 
 
Figure 2: Contractile forces are improved by intervention treatments in mdx diaphragm 
A: Bar charts and representative traces show weaker twitch force in mdx (n=6, gray line) 
compared with WT (n=6, black line) diaphragms and the effect of treatment with saline, 
(n=8, black line), monoclonal interleukin-6 receptor antibodies (xIL-6R) (n=6, gray line), 
urocortin 2 (Uro2, n=5, light gray line) and combined xIL-6R and Uro2 (n=7, dashed black) 
in mdx diaphragm tissue. B: Bar charts and representative traces show weaker tetanic force in 
mdx compared with WT diaphragms and the effect of treatment with saline, xIL-6R, Uro2, 
and combined xIL-6R and Uro2 in mdx diaphragm tissue. * and *** indicate p<0.05 and 
p<0.001, respectively.  
 
Figure 3: Diaphragm function is improved by combined xIL-6R and Uro2 treatment. 
Bar charts show A: peak specific shortening, B: peak specific mechanical work, C: peak 
specific velocity of contraction and D: peak specific mechanical power in saline-treated mdx 
mice compared with mdx mice treated with xIL-6R, Uro2 and combined xIL-6R and Uro2 
treatment. * indicates p<0.05. 
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